Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms

Area of Science:

• Cancer Biology
• Drug Resistance Mechanisms
• Molecular Oncology

Background:

• Secondary drug resistance in cancer is a significant challenge, often arising from clonal evolution following primary resistance.
• Understanding the mechanisms driving collateral resistance and their drug-specific pathways is crucial for effective cancer treatment, particularly in recurrent cases.

Purpose of the Study:

• To investigate the mechanisms by which cancer cells acquire collateral resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) after developing primary resistance to paclitaxel.
• To elucidate the distinct selection paths and cellular state alterations that occur during this resistance evolution.

Main Methods:

• Utilized resistance selection experiments to generate paclitaxel-resistant cancer cell populations.
• Conducted small-scale pharmacological screens to assess cross-resistance to EGFR-TKIs.
• Analyzed cellular pathways involved in stemness, metabolism, and apoptosis.

Main Results:

• Cancer cells with primary resistance to paclitaxel frequently develop collateral tolerance to EGFR-TKIs, forming more stable resistant populations.
• Paclitaxel-resistant cells exhibit distinct selection paths under EGFR-TKIs, characterized by enrichment of stemness programs.
• Observed a highly glycolytic adaptive stress response and rewiring of apoptosis control pathways in these resistant cells.

Conclusions:

• Paclitaxel failure induces significant alterations in cellular state, leading to collateral resistance to EGFR-TKIs.
• The findings highlight specific vulnerabilities associated with resistance evolution in the second-line treatment setting.
• This study provides insights into exploitable targets for overcoming acquired resistance in cancer therapy.